Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Product sales	$ 2,135,197	$ 1,631,926	$ 5,977,202	$ 4,629,407
Cost of product sales	920,935	658,542	2,564,775	1,954,752
Gross profit	1,214,262	973,384	3,412,427	2,674,655
Operating expenses
Research and development	496,874	329,527	1,600,144	953,026
Sales and marketing	816,025	677,033	2,399,131	1,819,778
General and administrative	1,039,223	1,263,272	3,637,333	3,514,678
Total operating expenses	2,352,122	2,269,832	7,636,608	6,287,482
Operating loss	(1,137,860)	(1,296,448)	(4,224,181)	(3,612,827)
Other income (expenses)
Interest income	30	4,729	2,394	18,448
Loss on disposal of property and equipment	(1,213)	0	(1,213)	0
Interest expense, related party	(33,334)	0	(41,667)	0
Amortization of debt discount	(93,598)	0	(124,797)	0
Write-off of deferred financing costs	0	0	(86,736)	0
Total other income (expenses)	(128,115)	4,729	(252,019)	18,448
Net loss	(1,265,975)	(1,291,719)	(4,476,200)	(3,594,379)
Net loss attributable to non-controlling interest	296,974	223,031	924,288	499,830
Net loss attributable to BioLife Solutions, Inc.	$ (969,001)	$ (1,068,688)	$ (3,551,912)	$ (3,094,549)
Basic and diluted net loss per common share attributable to BioLife Solutions, Inc. (in dollars per share)	$ (0.08)	$ (0.09)	$ (0.28)	$ (0.26)
Basic and diluted weighted average common shares used to calculate net loss per common share (in shares)	12,699,419	12,157,575	12,575,560	12,134,474